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Introduction: Heat/capsaicin skin sensitization is a well-characterized human experimental 
model to induce hyperalgesia and allodynia. Using this model, gabapentin, among other drugs, 
was shown to significantly reduce cutaneous hyperalgesia compared to placebo. Since the larger 
thermal probes used in the original studies to produce heat sensitization are now commercially 
unavailable, we decided to assess whether previous findings could be replicated with a currently 
available smaller probe (heated area 9 cm2 versus 12.5–15.7 cm2).
Study design and methods: After Institutional Review Board approval, 15 adult healthy 
volunteers participated in two study sessions, scheduled 1 week apart (Part A). In both sessions, 
subjects were exposed to the heat/capsaicin cutaneous sensitization model. Areas of hypersen-
sitivity to brush stroke and von Frey (VF) filament stimulation were measured at baseline and 
after rekindling of skin sensitization. Another group of 15 volunteers was exposed to an identical 
schedule and set of sensitization procedures, but, in each session, received either gabapentin 
or placebo (Part B).
Results: Unlike previous reports, a similar reduction of areas of hyperalgesia was observed in 
all groups/sessions. Fading of areas of hyperalgesia over time was observed in Part A. In Part B, 
there was no difference in area reduction after gabapentin compared to placebo.
Conclusion: When using smaller thermal probes than originally proposed, modifications of 
other parameters of sensitization and/or rekindling process may be needed to allow the heat/
capsaicin sensitization protocol to be used as initially intended. Standardization and validation 
of experimental pain models is critical to the advancement of translational pain research.
Keywords: experimental pain model, hyperalgesia, peripheral sensitization, central 
sensitization
Introduction
A reliable method to produce hyperalgesia and allodynia in human healthy volunteers 
could have a crucial role in the development of novel analgesic compounds by helping 
to bridge the gap between animal pain models and chronic pain patients.1,2 Hyperalgesia 
and allodynia are common symptoms experienced in chronic pain  syndromes3,4 and 
are thought to depend on central nervous system sensitization, which is maintained 
both by central mechanisms and ongoing peripheral stimuli.3–8 However, creating the 
experimental conditions to reliably induce central sensitization and test the reversal 
of established hyperalgesia is a complex task.9 The experimental model must be safe, 
tolerable, and induce sensitization lasting long enough to allow testing of both pre-
vention of hyperalgesia and reversal of established hypersensitivity without creating 
permanent damage.





One well characterized human experimental model of 
cutaneous sensitization is the heat/capsaicin model.1,10 This 
method uses the initial application of heat with a Peltier-type 
thermal probe, then topical capsaicin cream, and subsequent 
periodic thermal rekindling procedures to induce stable, 
reproducible, and long-lasting (up to 4 hours) hyperalgesia 
and secondary hypersensitivity in healthy human volunteers 
and patients.1,2,10–16
One advantage of the heat/capsaicin model is the abil-
ity to generate hypersensitivity of sufficient duration to test 
the onset and magnitude of drug analgesia without creat-
ing unacceptable discomfort, tissue injury, or long-lasting 
effects.1,10,17 The heat/capsaicin sensitization model has been 
applied successfully to demonstrate the ability of gabapentin, 
among other drugs, to reduce cutaneous hyperalgesia. These 
encouraging results, obtained with gabapentin, which is 
clinically effective in treating neuropathic pain, proved that 
the model could be used to predict clinical antihyperalgesic 
efficacy.16,18,19 However, the reproducibility of all experi-
mental pain models is influenced by multiple factors that 
may affect within-day and between-day variability of the 
subjects’ responses,17,20,21 and practical and logistical issues 
may limit the consistency of results between observers and/
or laboratories.
The size of the area directly stimulated with heat and 
capsaicin (area of “primary hyperalgesia”), and the resulting 
size of the surrounding area of secondary hyperalgesia may 
be critical factors in the reproducibility and applicability 
of this model.20,22 When first reported, the heat/capsaicin 
sensitization model used thermal stimulators with a heated 
surface area of 12.5–15.7 cm2.1,2,10–12,15,16 The heat/capsaicin 
model, as originally proposed, has become widely popular 
and extensively utilized in research; the methods have been 
reported in publications, lectures, and refresher courses at 
international meetings.1,10,23,24 However, since publication 
of the original report, the thermal probes that were utilized 
are no longer commercially available. The largest Peltier 
probe that is currently available has a heated surface area 
of 9 cm2.
As the intensity of the stimulus used to induce the cutane-
ous hyperalgesia has been shown to affect both extent and 
duration of the hyperalgesia,25,26 using the smaller thermode 
(9 cm2) may affect the size and duration of the area of second-
ary hyperalgesia both by heating a smaller area of skin and by 
providing a smaller contact surface to capsaicin cream (in this 
model the area covered with capsaicin cream corresponds to 
the thermode outline). This prompted us to question the pos-
sibility to reliably reproduce the model with a smaller area 
of peripheral sensitization. We knew that some researchers 
had been able to reproduce heat/capsaicin sensitization with 
smaller Peltier probes by utilizing modified procedures. The 
original papers by Petersen and Dirks1,10 were quoted as a 
source of the model in multiple studies by different groups 
in which, however, the protocol was significantly modified 
from the original, with different exposure time to capsaicin 
and/or different procedures of application or maintenance 
of the stimulus.27–30
Prior studies of analgesic responsiveness should be repli-
cated before adopting the 9 cm2 thermal probe as the standard 
for inducing heat/capsaicin cutaneous sensitization with this 
model, and, if a different heat/capsaicin model needs to be 
proposed as a standard, this would need to be validated on 
the basis of rigorous observations. The sequential application 
of heat and capsaicin will not always or necessarily produce 
reliable and stable sensitization. It is not known what are the 
essential elements of a model that associates heat and capsai-
cin to consistently create long lasting cutaneous sensitization; 
these factors may vary interindividually and also depend on 
the stimulation site and the outcomes observed. Using the 
9 cm2 Peltier thermode to induce cutaneous sensitization, 
the present study investigated the reproducibility of the heat/
capsaicin model as originally proposed1,10,16 by assessing: 
a) the size and duration of secondary hyperalgesia; and b) the 
antihyperalgesic response to a single oral dose of 1,200 mg 
gabapentin (the same single dose of gabapentin that had 
significantly decreased areas of hyperalgesia produced with 
the original heat/capsaicin model compared to placebo).16
Materials and methods
study subjects and design
The study was conducted in accordance with ethical prin-
ciples of Good Clinical Practice and the Declaration of 
Helsinki and its guidelines, and approved by Washington 
University in St Louis Institutional Review Board.
Subjects provided written informed consent after the 
study procedures were explained and their questions were 
answered, and before study procedures were initiated. A list 
of the inclusion and exclusion criteria, which were identical to 
the criteria utilized in the original study that we were seeking 
to replicate,16 is provided in Table 1, and demographic data 
are shown in Table 2.
In a screening/training session preceding the first study 
session, subjects were familiarized with the study procedures, 
including the induction of sensitization with sequential appli-
cation of heat and capsaicin (Figure 1A). During the first 
study session, heat/capsaicin sensitization was induced and 
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Table 1 inclusion and exclusion criteria
Inclusion criteria
 1. Male or nonpregnant, non-nursing female
 2. 18–50 years old
 3.  good general health with no remarkable medical conditions 
(eg, liver, kidney, heart, or lung failure)
 4. Body mass index between 20–33
 5. Unmedicated (excludes contraceptives)
 6. Willing to comply with study guidelines as outlined in protocol
 7. Willing to provide informed consent
Exclusion criteria
 1. anatomical malformation of upper extremities
 2. status post recent trauma or chronic lesions on either forearm
 3. Medication use (excludes contraceptives)
 4. history of allergy or intolerance to capsaicin
 5. history of allergy or intolerance to gabapentin
 6.  history of addiction to drugs or alcohol (prior or present addiction 
or treatment for addiction)
 7. history of chronic pain syndromes
 8. Pregnant and nursing females
 9. heat Pain Detection Threshold greater than 47°c at baseline
10.  Unable to achieve cutaneous sensitization with heat/capsaicin during 
the training session
Table 2 study subjects’ demographics
Part a – control group (15 subjects)
 Male (n): 7
 age (years): 30(±8)
 Race/ethnicity: White/caucasian, n=13; african-american, n=1; asian, n=1
 Body mass index 25.6(±3.6)
Part B – treatment group (15 subjects)
 Male (n): 7
 age (years): 26(±3)
 Race/ethnicity: White/caucasian, n=15
 Body mass index 26.4(±3)
maintained by rekindling the stimulation site with heat four 
times at regular intervals over the 4 hour study day. Areas of 
secondary allodynia, and hyperalgesia to foam brush and VF 
filament (primary outcomes); heat pain detection threshold 
(HPDT) in the stimulation site (secondary outcomes); and the 
painfulness of thermal stimulation (PTS) on nonsensitized 
skin (secondary outcomes) were determined multiple times 
during the study day. In all the study sessions, measurements 
were performed before the induction of sensitization (M0 in 
Figure 1B), after the first rekindling (RK1) (M1 in Figure 1B) 
and after the fourth rekindling (RK4) (M2 in Figure 1B). The 
study consisted of two parts:
Part A evaluated the natural history of sensory changes 
following heat/capsaicin sensitization. Subjects in this group 
underwent the procedures and measurements described above 
during two study sessions separated by at least 1 week to 
allow the skin to recover between sessions. In this group 
only, additional area, HPDT, and PTS measurements were 
repeated after RK2 and after RK3 to better follow the sen-
sory changes. Subjects in Part A will be referred to as the 
“control group”.
Part B was a double-blind, randomized, crossover study 
in healthy volunteers to evaluate the response to gabapentin 
using the heat/capsaicin model. On the first study session, 
subjects were randomly assigned to receive a single oral 
dose of gabapentin (1,200 mg) or placebo immediately after 
induction of the heat/capsaicin sensitization as previously 
described by Dirks et al.16
Outcome measures were collected as described above 
(baseline, pre-drug and post-drug; for detail see Figure 1B). 
During the second study session, subjects underwent the 
same procedures but received the treatment that they had not 
received during their first session. Sessions were 1 week apart 
to allow washout of the treatment administered in the first 
session. Areas obtained after gabapentin/placebo administra-
tion (M2 in Figure 1B) were compared to postsensitization 
baseline areas (M1 in Figure 1B) and the results obtained with 
gabapentin and placebo were compared. Subjects in Part B 
will be referred to as the “gabapentin/placebo group”.
Sample size estimate was based on the previously pub-
lished between-days coefficients of variation of the areas of 
hyperalgesia obtained with this model.1 In the methodologi-
cal study aimed at validating the heat/capsaicin model,1 the 
authors calculated sample sizes needed to detect treatment 
differences with this model, based on the coefficients of varia-
tion of areas of hyperalgesia within-day and between-day. 
Assuming for our study the same coefficients of variation, 
and planning a between-days comparison and a cross-over 
design, we recalculated the sample size to obtain a probability 
of 80% that the study could detect a treatment difference at 
a two-sided 0.05 significance level, if the true difference in 
area reduction between treatments (gabapentin and placebo) 
was at least 30% (in the original study, comparing gabapen-
tin and placebo with this model, the observed difference in 
area reduction was about 70%). Our sample size calculation 
indicated that 15 subjects were necessary in the treatment 
group. An equal number of subjects were enrolled in the 
control group for comparison.
Forty-nine subjects provided written consent and were 
enrolled in the study. Seventeen subjects did not meet 
inclusion criteria during the screening session and two 
more were excluded during the study as they met exclu-
sion criteria after enrollment. The remaining 30 subjects 
completed Part A (n=15) or Part B (n=15) of the study. The 
15 subjects who took part in Part B of the study were assigned 





to receive placebo or gabapentin on their first study session 
by a computer generated randomization table. Subjects and 
investigators directly involved in data collection and analysis 
were blinded to the treatment allocation. The randomization 
sequence was provided by the investigational pharmacy, 
and a research nurse not directly participating in the study 
managed the schedule and assigned subjects to interventions. 
Of the 15 subjects who completed Part B, one subject was 
excluded from the analysis because the blood sample col-
lected on the placebo day contained gabapentin, indicating a 
possible confusion in the blood sample analysis or erroneous 
administration of gabapentin on the placebo day. A flow 
diagram of enrollment and allocation of subjects in the study 
is shown in Figure 2.
study measurements and procedures
All study procedures were maintained identical to the original 
protocol16 and performed by the same investigator (KF) in 
a quiet environment, at controlled room temperature, with 
subjects comfortably sitting in a hospital bed or recliner 
with armrests.
heat/capsaicin sensitization procedure
Thermal stimulations were applied in a precise and con-
trolled manner using a Medoc Advanced Thermal Stimulator 
(Medoc Ltd., Ramat Yishai, Israel) driving a 9 cm2 thermode. 
An area of the skin on the volar surface of the dominant 
forearm of each subject was chosen, and the distance of the 
center of this area from the elbow crease and from the wrist 
A)  Timeline of screening/training day procedures
B)  Timeline of study day procedures – sessions 1 and 2
Start HC

























Figure 1 Timeline of training and study sessions. The procedures performed in each session are illustrated. (A) screening/training day and (B) study days.
Notes: in the control group there was no drug administration, and additional sets of the same measurements described below (M) were taken after RK2 and RK3. in the 
gabapentin/placebo group, on session 1 and 2, subjects were randomly assigned to receive gabapentin or placebo. M refers to a set of measurements (mapping of area of 
hyperalgesia/allodynia, heat pain detection threshold, pain during thermal stimulation).
Abbreviations: hc, heat/capsaicin sensitization; RK, rekindling.
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crease was recorded to keep the site of the area consistent 
between sessions. Heat was applied to this previously delim-
ited area using the thermode, which ramped from 32°C to 
45°C at a rate of 1°C per second and then held at 45°C for 
5 minutes. During these 5 minutes, subjects used an elec-
tronic handheld device to rate their pain every minute by 
moving a bar on a 0–10 visual analog scale (VAS), where 
0 indicates “no pain” and 10 indicates “the most intense 
pain imaginable.” The handheld device was connected to a 
computer that recorded the ratings on a 0–100 scale. The 
heating procedure was followed by immediate application of 
capsaicin cream (Capzasin-HP cream [previously 0.075%, 
now marketed as 0.1%], Chattem Inc., Chattenooga, TN, 
USA) covering the heated surface (outline of thermode). 
The cream was left on for 30 minutes and then gently wiped 
off in one single motion, taking care in avoiding rubbing 
the cream into the skin. Approximately 0.5 oz of cream was 
required to cover the entire surface completely. Subjects were 
asked to rate their pain on the handheld VAS at the start of 
the 30 minute period and then for every 5 minutes until the 
cream was removed.
Rekindling
On study days, hypersensitivity was maintained by 
 “rekindling” the site of heat/capsaicin application. This 
was accomplished by restimulating the previously treated 
skin four times at 45-minute intervals with the thermode 
 increasing from 32°C to 40°C at a rate of 1° per second and 
held at 40°C for 5 minutes. Subjects rated their pain on a 
continuous VAS during rekindling.
Mapping of areas of hypersensitivity
The borders of secondary allodynia and hyperalgesia were 
mapped using a 1 inch foam brush and a 26 g VF filament 
(26 g bending force [North Coast Medical, Gilroy, CA, 
USA]). Subjects were asked to close their eyes while the 
brush was applied along four linear paths between the ther-
mode outline and: 1) the antecubital fossa; 2) the wrist; 3) 
the lateral forearm; and 4) the medial forearm. Stimulation 
was started distant from the borders of the heated area and 
worked closer in 5 mm steps at 1-second intervals. Subjects 
were instructed to recognize a “distinct change in sensa-
tion” such as “increased burning, tenderness, more intense 
pricking, or an unpleasant sensation,” and that location was 
marked. This procedure was then repeated with the VF fila-
ment. Areas of hypersensitivity were calculated (in cm2) as 
the distance between the farthest points marked on the rostral/
caudal axis multiplied by the distance between the farthest 
points marked on the medial/lateral axis. The presence of 
cutaneous hypersensitivity was assessed before the induction 
of sensitization (M0 in Figure 1A and B), after RK1 (M1 in 
Figure 1B), and after RK4 (M2 in Figure 1B). Two additional 
measurements (after RK2 and after RK3) were taken in Part 
A of the study.
heat pain detection threshold
The threshold for heat pain detection was determined by using 
a thermal ramp protocol on the marked location on the volar 
surface of the forearm. The temperature applied through the 
thermode was increased from 32°C to the 50°C safety cutoff 
at 1°C per second. Subjects were asked to turn off the heated 
thermode by depressing a button at “the lowest temperature 
that they perceived as painful.” Four thermal ramps were 
performed 10 seconds apart and their median value was 
calculated. To avoid testing individuals whose pain threshold 
approached the safety cutoff, subjects with HPDTs greater 
than 47°C were excluded from the study. HPDT was assessed 
before the induction of sensitization (M0 in  Figure 1A 
and B), after RK1 (M1 in Figure 1B), and after RK4 (M2 in 
Figure 1B). Two additional measurements (after RK2 and 
after RK3) were taken in Part A of the study.
Pain during thermal stimulation
Acute pain was induced by a 1-minute 45°C heat stimulus on 
a marked location on the upper nondominant arm (deltoid). 
Subjects were asked to rate their pain intensity during the 
49 subjects screened
17 excluded at screening*
15 enrolled in Part B







1 excluded from analysis
(gabapentin found in plasma
on placebo session day)
Randomization
2 excluded for HPDT >47°C on session 1
Figure 2 enrollment and allocation of participants in the study.
Note: *Reasons for exclusions on screening day: 5= hPDT .47°c; 9= unable to 
achieve sensitization (area); 1= admitted history of drug abuse; 1= showed lesions 
on forearm at physical examination; 1= body mass index .33.
Abbreviation: hPDT, heat pain detection threshold.





1-minute heat stimulus continuously using the electronic 
VAS, as described above. PTS was assessed before the 
induction of sensitization (M0 in Figure 1A and B), after 
RK1 (M1 in Figure 1B), and after RK4 (M2 in Figure 1B). 
In Part A of the study, PTS was also assessed after RK2 and 
after RK3.
Measurement of plasma concentration of gabapentin
All subjects in the drug/placebo group had a blood sample 
(5 mL) collected from the nondominant arm to assess 
gabapentin plasma concentration at 150 minutes after drug/
placebo administration (for preservation of blinding in the 
protocol, the sample was collected in both sessions). Plasma 
was frozen for later analysis.
Gabapentin was quantitated using LC/MS/MS (liquid 
chromatography and tandem mass spectrometry). Plasma 
samples were thawed, vortexed, and aliquots of 475 µL of 
sample, standard or quality control sample, were transferred 
into a deep well 96-well plate. To each well were added 
0.25 mL of 1 M sodium phosphate buffer and 25 µL of 
a 0.5 µg/mL Gabapentin D10 internal standard solution 
prepared in water (Sigma-Aldrich, St Louis, MO, USA). 
Samples, standards, and quality controls were then applied 
to a Bond Elut C18 solid phase extraction plate (Agilent 
Technologies, Böblingen, Germany), which had been pre-
pared by washing first with 1.0 mL of methanol and then with 
1.0 mL of 1 M sodium phosphate buffer. After applying the 
samples to the extraction plate it was washed with 1.0 mL 
of 0.1 M sodium phosphate buffer and then with 1.0 mL of 
0.1 M hydrochloric acid. Samples were eluted with 1.0 mL 
of methanol and the plate dried down at 30°C under a gentle 
flow of nitrogen. Samples were reconstituted with 500 µL of 
mobile phase: 95% 4.5 mM ammonium acetate in water/5% 
4.5 mM ammonium acetate in acetonitrile. The deep well 
plate was shaken for 10 minutes and 200 µL was transferred 
to a 96-well autosampler plate. Calibrators (8 concentrations 
over the range 0.5 to 50 ng/mL) and three quality control 
samples (3, 15, and 30 ng/mL) in human plasma were pre-
pared along with experimental samples.
Instrumental analysis was performed on an API 4000 
QTRAP triple-quadropole mass spectrometer (Life Technolo-
gies, Carlsbad, CA, USA) equipped with a Turbo IonSpray 
Source. A Shimadzu UFLC system (Shimadzu Corpora-
tion, Kyoto, Japan) that consisted of a CMB-20A system 
 controller, two LC-20ADXR pumps, a DGU-20A3 degas-
ser, a SIL-20AC autosampler, and a CTO-20A column oven 
was used to deliver the samples to the  detector. An external 
two-way Valco valve (Valco Instruments Co. Inc., Houston, 
TX, USA) was utilized to direct  high-performance liquid 
chromatography flow to waste before and after column 
elution of analytes of interest. Chromatographic separa-
tion was performed on a Kinetix 2.6 µm C18 analytical 
(2.1 by 100 mm) column (Phenomenex Inc., Torrance, CA, 
USA) with a Security Guard ULTRA C18 guard cartridge 
for 2.1 mm ID columns installed prior to the analytical 
column  (Phenomenex). Before each injection, the needle 
was washed with 10% isopropanol. Mobile phase A was 
4.5 mM ammonium acetate in water and mobile phase B 
was 4.5 mM ammonium acetate in acetonitrile. Mobile 
phase was delivered at initial conditions of 5% B at a flow 
rate of 0.3 mL/minute with the following time program: hold 
at 5% B for 0.6 minutes followed by a linear gradient over 
0.65 minutes between 5% and 95% B; hold at 95% B for 
1.25 minutes; mobile phase composition is then brought back 
down to initial condition of 5% over 0.01 minutes. The col-
umn was re-equilibrated with 5% B from 2.51 to 4.0 minutes. 
The retention time for gabapentin was 2.2 minutes under 
these conditions. Both Q1 and Q3 quadrupoles of the mass 
spectrometer were optimized to unit mass resolution. The 
instrument was operated in positive-ion mode with an ion 
spray voltage of 5,500 volts and a temperature of 450°C. 
The curtain gas was set at 20 pound per square inch (psi), 
ion source gas 1 at 30 psi, gas 2 at 40 psi, and the collision 
gas was set to medium.  Gabapentin and the internal stan-
dard were detected by multiple reaction monitoring, using 
the transitions m/z 172→137 and 182→104, respectively. 
Quantitation was performed in Analyst software version 
1.5.2 (Life Technologies).
statistical analysis
Our primary outcome measure was the size of the areas of 
hyperalgesia to punctate stimuli (VF filament stimulation) 
and dynamic tactile allodynia (brush stimulation) outside 
the area directly exposed to heat and capsaicin, ie, the areas 
of secondary hyperalgesia. Secondary outcome measures 
included HPDT in the area directly stimulated with heat and 
capsaicin (ie, the area of primary hyperalgesia), painfulness 
of the rekindling procedures quantified by visual analog scale 
(handheld device on a 0–10 scale translated in electronic VAS 
on a 0–100 scale), and painfulness of a one minute 45°C 
stimulation in normal skin (pain during thermal stimulation, 
PTS as quantified by VAS).
Data were analyzed with Analyse-it (Analyse-it 
 Software, Ltd., Leeds, UK) version 2.26. Appropriate data 
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transformations and nonparametric methods were used as 
indicated. Measurements of areas of hypersensitivity were 
normalized for each subject using the baseline measure-
ments, so that the final outcome is expressed as the percent 
of baseline area. Measures of area changes, HPDT, and 
VAS during thermal stimulation (PTS) are expressed as 
medians as well as 1st and 3rd quartiles of the values for 
each subject at each chosen time point. Measures of VAS 
during rekindling procedures are expressed as mean and 
standard deviation. Comparisons of data sets were performed 
with Student’s t-test and Wilcoxon test for paired data, and 
one-way ANOVA and Friedman test for repeated measures. 
A P less than 0.05 was considered statistically significant. 
For all analyses, careful attention was given to whether the 
data satisfied the distributional and model-specific assump-
tions of the procedures used.
Results
areas of secondary hypersensitivity  
to VF and foam brush stroke stimulation
study sessions (Parts a and B)
Areas of hypersensitivity to VF stimulation and brush stroke 
and red flare as expected were obtained after sensitization 
with heat and capsaicin in all subjects in both Parts A and B of 
this study. However, in contrast to what has been previously 
reported,1,10,16 it was not possible to maintain these areas as 
stable with rekindling procedures throughout the study day. 
The areas of hypersensitivity tended to fade spontaneously 
in the absence of pharmacological intervention (Part A), and 
no significant difference was observed in reduction of areas 
of secondary hyperalgesia and allodynia after treatment with 
gabapentin compared to placebo (Part B).
After gabapentin administration, post-RK4 (M2 in 
Figure 1B), the areas of secondary hyperalgesia to VF stimu-
lation and allodynia to brush stroke were reduced to 65% 
(34.3%–85.3%) and 32.8% (0%–76.7%), respectively, of the 
areas measured at post-RK1 (M1 in Figure 1B). After placebo 
administration, areas mapped by VF stimulation and brush 
stroke were reduced to 78.4% (46.4%–84.9%) and 42.9% 
(34.6%–56.2%), respectively. Similar results were observed 
in the control group (Part A) that did not receive either pla-
cebo or drug (in Session 1, post-RK4 VF areas were reduced 
to 56% [34.6%–87%] of post-RK1 area, and brush areas 
were reduced to 40.3% [31.6%–79.6%] of post-RK1 area. In 
Session 2, VF areas were reduced to 67.1% [41.5%–86.2%], 
and brush areas were reduced to 55% [22.5%–73.3%%]). 
These reductions of the areas of hypersensitivity were not 
significantly different between treatment sessions in any 
group (Figure 3A–D).
heat pain detection thresholds
HPDTs were measured to evaluate increased heat sensitivity 
in the area of primary sensitization. HPDTs at M0 (Figure 1B) 
were not different between sessions in any group.
Training session
On the training day, subjects enrolled both in Part A and Part 
B of the study showed significantly decreased HPDTs imme-
diately after induction of sensitization with heat and capsaicin 
(M-test in Figure 1A) compared to baseline presensitization 




In the control group, baseline HPDTs before sensitization 
(M0 in Figure 1B) were not different between treatment 
sessions (P=0.8). HPDTs postsensitization were not differ-
ent from M0 at any time point (post-RK1 through RK4), 
or in any of the two study sessions (Session 1 P=0.16 and 
Session 2 P=0.09).
Part B
In the gabapentin/placebo group, baseline HPDTs before sen-
sitization (M0 in Figure 1B) were also not different between 
treatment sessions (P=0.58).
After RK1 (M1 in Figure 1B), HPDTs were significantly 
lower than M0 in the placebo session (P=0.03), but were 
not significantly different to M0 in the gabapentin session 
(P=0.28). On the placebo day, post-drug HPDTs (M2 in 
Figure 1B) showed no difference with M1 (P=0.9) and 
remained significantly lower than M0 (P=0.002) (Figure 4).
In the gabapentin session, post-drug HPDT measurements 
at M2 were not different compared to both M0 and to M1 
(P=0.08 and P=0.7, respectively).
Post-drug (M2) HPDTs were not significantly different in 
the gabapentin session compared to the placebo session (41.7°C 
[40.8°C–42.8°C] versus 41.4°C [40.6°C–42.4°C]; P=0.41).
Vas scores during rekindling procedures
study session (Part a and Part B)
In both Part A and Part B of the study, pain reported by sub-
jects during RK1 and RK4, respectively, remained constant 
throughout the 5 minute procedure in both sessions (analysis 





was performed with one-way ANOVA to test for differ-
ences of VAS over time; 5 time-points, 1 minute apart, were 
 considered). In the absence of significant differences in VAS 
scores recorded in the course of the 5 minutes, it was decided 
to use cumulative mean VAS scores obtained during RK1 and 
RK4 to evaluate potential differences between groups (mean 
VAS score during RK1 and RK4) and within group (mean 
VAS score at RK1 versus mean VAS score at RK4).
In the control group (Part A), the mean VAS score over 
5 minutes at RK1 was 32 (standard deviation [SD] 20.3) in 
120 Baseline (M1)
Post RK4 (M2)
Area of secondary hyperalgesia
(to VF stimulation)
No treatment (part A – control group)
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Figure 3 areas of secondary hyperalgesia and allodynia.
Notes: Percentage change of area size after treatment in the placebo/gabapentin group and at the same time-point, after the fourth rekindling, in the control group (M2) 
compared to baseline (M1); data are presented as medians, 1st, and 3rd quartiles; P-values refer to comparison of percentage changes in VF and brush areas between sessions 
(control group) and between treatments (placebo/gabapentin group). a P-value less than 0.05 was considered statistically significant.
Abbreviations: RK, rekindling; VF, von Frey.
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and capsaicin application compared to baseline (M0) at any 
time point (M1 and M2). In particular, in Part B, as expected, 
painfulness did not differ after placebo or gabapentin admin-
istration (P=0.13).16
Plasma concentrations of gabapentin
Median plasma concentration measured 150 minutes after 
drug administration (post-M2 in Figure 1B) was 4.3 µg/mL 
(3.1–6.0 µg/mL). There was no correlation between plasma 
concentration of gabapentin and reduction of areas of hyper-
algesia (R2=0.003) or allodynia (R2=0.035).
Discussion
In our study, areas of sensitization to VF and brush stimula-
tion faded over time independent of the treatment admin-
istered (gabapentin or placebo), and also in the absence of 
any treatment (control group). Interestingly, the spontaneous 
fading of areas despite rekindling procedures (Figure 5) 
was consistent with the previously demonstrated spontane-
ous decay of these areas in the absence of ongoing heat 
stimulation.10 In the original study by Petersen and Row-
botham,10 in the absence of rekindling (40°C for 5 minutes 
every 40 minutes for over 3 hours), the areas of secondary 
hyperalgesia and allodynia “decreased steadily during the 
study period, demonstrating the necessity of ongoing noci-
ceptor input.” Indeed, in our study, the area sizes decreased 
steadily despite “ongoing nociceptor input” whereas, in the 
original study, rekindling procedures maintained stable areas 
of hypersensitivity “for at least 4 hours” after induction of 
sensitization.10
As previously observed,1,10,17,31 we also found that brush 
areas were consistently smaller than VF areas at each time 
point. In contrast with prior observations,10 initial areas of 
hyperalgesia to VF stimulation obtained in session 2 (as 
measured post-RK1) were smaller than areas obtained in 
session 1 (P=0.02), while the difference in initial brush areas 
between the two sessions did not reach statistical significance 
(P=0.09; Figure 5). The difference in areas of hyperalgesia 
between the two sessions may simply reflect the instability 
of these areas, while the absence of a significant difference 
in areas of mechanical allodynia between sessions may indi-
cate a lack of power of our study to detect small differences 
between these already small areas. As previously reported, 
intrinsic differences in the type of applied mechanical 
stimuli underlie the different behavior of the areas obtained: 
brush stimulation is thought to activate mainly Aβ fibers, 









































Figure 4 hPDTs in the treatment group.
Notes: HPDT changes at the first and second set of measurements (M1 and M2, 
respectively) are compared to presensitization baseline (M0) in the gabapentin 
and the placebo sessions; data are presented as medians, 1st, and 3rd quartiles; 
significantly different couples of measurements are indicated: #P=0.03; *P=0.002. 
(a P-value less than 0.05 was considered statistically significant). In the placebo 
group HPDTs remained significantly different than baseline at each time point after 
induction of heat/capsaicin sensitization.
Abbreviations: hPDT, heat pain detection thresholds; RK, rekindling.
session 1 and 32.5 (SD 22.5) in session 2. The mean VAS 
score over 5 minutes at RK4 was 15.3 (SD 15.7) in session 1 
and 9.9 (SD 12.8) in session 2.
In the treatment group (Part B), the mean VAS score at 
RK1 was 40.2 (SD 18) on the placebo day and 40.4 (SD 21.5) 
on the gabapentin day, and the mean VAS score at RK4 was 
21.3 (SD 19.8) on the placebo day and 19.7 (SD 18.3) on 
the gabapentin day.
VAS scores at RK4 were significantly lower than scores 
at RK1 in all sessions, independent of the treatment (or no 
 treatment). In particular, in Part A, both in session 1 and 
session 2, VAS scores during RK4 were lower than scores 
during RK1 (session 1: P,0.0025 and session 2: P,0.0009; 
Figure 6A). In Part B, both on placebo and gabapentin day RK4 
(post-drug) VAS scores were significantly lower than RK1 scores 
(P,0.00005 and P,0.00001, respectively; Figure 6B).
PTs
study sessions (part a and part B)
In both Part A and Part B, median and maximum pain scores 
measured by VAS were not significantly different after heat 





Significantly decreased HPDTs after heat and capsaicin 
application confirmed the creation of primary sensitization 
with this model, as previously demonstrated.10,16 However, 
unlike previous reports areas of secondary hypersensitivity 
were not stable. Stable areas would have been necessary to 
test gabapentin’s effectiveness in suppressing established 
cutaneous sensitization compared to placebo. The persistent 
reduction of HPDTs after RK4 (M2) compared to baseline 
presensitization (M0) in the placebo session may indicate a 
tendency toward reaching an adequate intensity of stimula-
tion to sustain the area of primary heat hyperalgesia through 
the rekindling procedures. However, a similar effect was not 
present in the control group.
While the initial heat/capsaicin stimulation was sufficient 
to create an area of primary hyperalgesia, characterized by 
hypersensitivity to heat/pain stimulation,10,31,32 the rekindling 
procedures were not adequate to maintain it.
Previous studies have demonstrated that the size of the 
primary area of sensitization may be a critical factor in cre-
ating and maintaining an area of secondary sensitization to 
both heat and mechanical stimulation.20,33 Three main fac-
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Figure 5 Brush and von Frey areas: spontaneous fading despite rekindling procedure in control group.
Notes: spontaneous fading of Brush areas (A and B) and von Frey areas (C and D) despite rekindling procedures is shown in the control group. Data are presented as 
medians, 1st, and 3rd quartiles. Initial von Frey areas in session 2 are significantly smaller than session 1: *P,0.02 (a P-value less than 0.05 was considered statistically 
significant).
Abbreviation: RK, rekindling.
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of areas of secondary sensitization: intensity of the painful 
stimulation;25 duration of the noxious stimulation (continu-
ous or repeated exposure over time);1,34,35 and size of the area 
subject to primary sensitization.20,33 An adequate combination 
of these three elements appears to be critical to maintain a 
nociceptive input barrage strong enough to sustain central 
sensitization. Establishing a “critical size” (in absolute or 
even relative terms) to obtain a “sensitization outcome” of a 
predictable duration and magnitude with this model – similar 
to the Minimal Erythema Dose utilized by Gustorff et al in 
the UVB burn model9,36 – may prove difficult due to the con-
tribution of multiple factors to this effect (including time of 
exposure, intensity of the two noxious stimuli, and intrinsic 
characteristics of the subject).9,37,38 However, much like it 
has been hypothesized for secondary hyperalgesia to heat,33 
the development and persistence of secondary hyperalgesia 
to mechanical stimulation in this experimental model seems 
to critically depend on the magnitude and intensity of the 
stimulation in the area of peripheral sensitization.39
Yucel et al could not confirm stable areas of secondary 
hyperalgesia and allodynia by associating heat pre- and 
postconditioning to topical capsaicin application.20 In Yucel 
et al’s study, conditioning with heat in an attempt to “rekindle 
the spontaneous afferent C-fiber input” did not have any 
effect on the ongoing pain ratings and sensory test results 
(VF and brush stimulation).20 Use of a smaller probe, shorter 
rekindling, and lower temperatures than utilized by Petersen 
and Rowbotham10 were examined by the authors as possible 
causes of failure to obtain stable areas of hypersensitization. 
They observed that “the duration and stability of secondary 
hyperalgesia seems to depend on both the intensity of the 
initial stimulus and on continued nociceptive input.”20 Our 
findings are consistent with this observation.
In the absence of sufficient ongoing nociceptive input, 
areas of secondary hyperalgesia rapidly and spontaneously 
decline,32 making it difficult to appreciate potential differ-
ences between treatments aimed at reducing these areas as 
the differences, proportionally, tend to become smaller over 
time. Indeed, in our study, areas of secondary hyperalgesia at 
baseline were smaller than areas previously obtained with this 
model using larger thermal probes for induction. Our average 
VF areas tested immediately after induction of heat/capsaicin 
sensitization (M-test in Figure 1A) were 85 cm2 for female 
subjects (groups pooled, n=16) and 78 cm2 for male subjects 
(n=14); brush areas were 43 cm2 for females and 48 cm2 for 
males. These areas were significantly smaller than the areas 
obtained from a series of studies conducted with a larger 
heated probe (15.7 cm2 surface area thermode [Medoc TSA 
2001; Medoc Ltd.]).40 Data from these studies were pooled 

































Figure 6 Mean Vas scores for each minute during the 5-minute RK preceding the sets of measurements M1 (RK1) and M2 (RK4).
Notes: Mean Vas scores for each minute during the 5-minute RK preceding the sets of measurements M1 (RK1) and M2 (RK4). Data are presented as means and standard 
deviations. (A) session 1 and 2 of the control group are compared; (B) Placebo day and gabapentin day of the treatment group are compared. in both groups and both 
study sessions, painfulness at each minute of the rekindling procedures decreased significantly between the first and fourth rekindling, despite treatment (or no treatment). 
Part a: both in session 1 and session 2, Vas scores during RK4 were lower than scores during RK1 (session1: P,0.0025 and session 2 P,0.0009). Part B: both on placebo 
and gabapentin day RK4 (post-drug), VAS scores were significantly lower than RK1 scores (P,0.00005 and P,0.00001, respectively). a P-value less than 0.05 was considered 
statistically significant.
Abbreviations: RK, rekindling procedure; Vas, visual analog scale.





Petersen. In 85 healthy subjects (41 females/44 males) the 
mean VF areas were 126 cm2 for female and 153 cm2 for 
males, and the mean brush area was 107 cm2 for females 
and 112 cm2 for males.40
The area of secondary hyperalgesia at baseline has been 
considered a determinant of assay sensitivity in the intra-
dermal capsaicin model.22 Using this model to evaluate the 
effect of different treatments on capsaicin induced secondary 
hyperalgesia and allodynia, Wang et al found that increasing 
precision for discrimination of active treatment from placebo 
was associated with increasing the area of secondary hype-
ralgesia at screening of the subjects.22
Our selection criteria for healthy volunteers, study pro-
cedures, and all other measurable variables, other than the 
smaller size thermode, were consistent with those used in 
prior placebo-controlled studies in which the model created 
stable, long-lasting areas of hypersensitivity and secondary 
hyperalgesia, adequate to test the effect of different drugs 
on experimental cutaneous hyperalgesia.2,15,16 Therefore, our 
hypothesis is that the main contributing factor to our inability 
to maintain stable areas of sensitization was the relatively 
undersized thermode, which produced smaller areas of hyper-
sensitivity, and failed to produce adequate nociceptive input 
to maintain these areas through the rekindling procedures.
When this smaller thermode is used to produce cutane-
ous sensitization in association with capsaicin, a sufficient 
ongoing nociceptive input might be provided by prolonging 
exposure to capsaicin28 or increasing the number and fre-
quency of the rekindling procedures. In a functional mag-
netic resonance imaging (fMRI) study on pharmacological 
modulation of pain-related brain activity during normal and 
central sensitization states, Iannetti et al28 utilized the 9 cm2 
thermode to produce heat/capsaicin cutaneous sensitization 
on the shin area of the legs of 12 healthy male volunteers. 
The main finding of this study is that gabapentin has a major 
modulatory effect on fMRI brain responses to nociceptive 
inputs during central sensitization.28
In contrast to our study, Iannetti et al28 administered 
gabapentin before induction of sensitization, and heat and 
capsaicin were applied at the time of the expected plasmatic 
peak of gabapentin. In addition, the fMRI scan was started 
only 1 hour after induction of the model, and the capsaicin 
cream was not removed from the skin until the end of the 
scanning period, resulting in a total time of capsaicin appli-
cation of approximately 100 minutes versus 30 minutes in 
the study reported here. In these conditions, which were 
modified from the original model, the cutaneous sensitiza-
tion was maintained by extending the exposure to capsaicin. 
The effects of gabapentin in modulating brain activity in 
enhanced pain states were evaluated by fMRI activity dur-
ing this “prolonged induction” phase, and no rekindling 
procedures were performed to maintain the sensitization 
after this initial phase.
Baseline pain measured with VAS during PTS on the 
nondominant upper arm (LTS [long thermal stimulation] in 
the original study by Dirks et al)16 was not different between 
groups on the training day nor on any of the study days. Pain 
scoring was not significantly different after heat and capsaicin 
application compared to baseline (pre-heat/capsaicin applica-
tion) in any group, and, as expected,16,41 painfulness did not 
differ after placebo or gabapentin administration. Similarly, 
in the area of primary sensitization, no difference was noted 
in pain scores obtained during matched rekindling procedures 
between sessions (eg RK1 versus RK1 in different study 
days), and, regardless of the treatment, VAS scores during 
RK4 were lower than VAS scores during RK1.
Arguably, our plasma concentrations of gabapentin 
(average 4.3 µg/mL) might have been too low to detect a 
significant effect of gabapentin compared to placebo in our 
conditions.41,42 However, our concentrations were in the 
range of therapeutic plasma concentrations (2–15 µg/mL), 
and the route, dose, and administration schedule that we used 
were consistent with the original protocol that we sought 
to reproduce,16 where gabapentin demonstrated significant 
antihyperalgesic efficacy.
Since we did not have a comparably sized thermode as 
described in prior studies, we were not able to test whether 
we could reproduce the model with a larger thermal probe. 
Indeed, the fact that larger heating probes are not currently 
commercially available was one of the reasons why we were 
interested in assessing whether a smaller probe could repro-
duce reported results obtained with this model.
Conclusion
The ability to create long-lasting and stable areas of sen-
sitization set the heat/capsaicin model apart from other 
models of experimental cutaneous sensitization, and made 
it suitable to study reversal of established hyperalgesia. The 
heat/capsaicin model, as originally proposed, has become 
widely popular, and extensively reported and utilized in pain 
research.  However, size, duration, and intensity of noxious 
stimulation have been shown to be critical for the induc-
tion and maintenance of areas of secondary hyperalgesia in 
multiple conditions. In our experimental setting, all other 
controllable variables were consistent with the original pro-
tocol that we were seeking to replicate, except for the use of 
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a smaller size thermode, and, in these conditions, we could 
not confirm previous findings of a significant difference 
between gaba pentin and placebo in reducing areas of heat/
capsaicin induced cutaneous sensitization. We hypothesized 
that the reduction in area of sensitization observed after 
placebo might depend on a spontaneous fading of the area 
as opposed to a “placebo effect”, which had not been previ-
ously observed.
To our knowledge, this is the first study demonstrating 
the inability to reproduce the original heat/capsaicin cuta-
neous sensitization model by applying the critical “ongoing 
nociceptive input” on a smaller surface area than originally 
reported. Additionally, we hope that our negative result will 
bring focus on the significant issue of standardizing and 
validating experimental pain models. The advancement of 
translational pain research strictly depends on the availability 
of experimental pain models and methods that can be easily 
and consistently reproduced, so that they can be uniformly 
applied and provide results that are significant, predictive of 
clinical efficacy, and comparable among different studies.
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